- Home
- AWP vs MREO Comparison
AWP vs MREO Comparison
Compare AWP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWP
- MREO
- Stock Information
- Founded
- AWP 2007
- MREO 2015
- Country
- AWP United States
- MREO United Kingdom
- Employees
- AWP N/A
- MREO N/A
- Industry
- AWP Trusts Except Educational Religious and Charitable
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- AWP Finance
- MREO Health Care
- Exchange
- AWP Nasdaq
- MREO Nasdaq
- Market Cap
- AWP 352.4M
- MREO 369.2M
- IPO Year
- AWP N/A
- MREO N/A
- Fundamental
- Price
- AWP $3.86
- MREO $2.22
- Analyst Decision
- AWP
- MREO Strong Buy
- Analyst Count
- AWP 0
- MREO 7
- Target Price
- AWP N/A
- MREO $7.71
- AVG Volume (30 Days)
- AWP 331.5K
- MREO 1.3M
- Earning Date
- AWP 01-01-0001
- MREO 03-26-2025
- Dividend Yield
- AWP 12.48%
- MREO N/A
- EPS Growth
- AWP N/A
- MREO N/A
- EPS
- AWP N/A
- MREO N/A
- Revenue
- AWP N/A
- MREO N/A
- Revenue This Year
- AWP N/A
- MREO N/A
- Revenue Next Year
- AWP N/A
- MREO $69.09
- P/E Ratio
- AWP N/A
- MREO N/A
- Revenue Growth
- AWP N/A
- MREO N/A
- 52 Week Low
- AWP $3.06
- MREO $2.23
- 52 Week High
- AWP $4.20
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- AWP 46.56
- MREO 33.19
- Support Level
- AWP $3.77
- MREO $2.23
- Resistance Level
- AWP $3.91
- MREO $2.73
- Average True Range (ATR)
- AWP 0.06
- MREO 0.14
- MACD
- AWP 0.00
- MREO -0.01
- Stochastic Oscillator
- AWP 44.44
- MREO 7.89
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).